Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · IEX Real-Time Price · USD
1.020
+0.062 (6.52%)
At close: Jul 19, 2024, 4:00 PM
1.010
-0.010 (-0.98%)
Pre-market: Jul 22, 2024, 7:28 AM EDT
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $473.54K in the twelve months ending March 31, 2024, with 283.80% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $148.00K with 124.24% year-over-year growth. In the year 2023, Ovid Therapeutics had annual revenue of $391.70K.
Revenue (ttm)
$473.54K
Revenue Growth
+283.80%
P/S Ratio
152.82
Revenue / Employee
$11,838
Employees
40
Market Cap
72.36M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 391.70K | -1.11M | -73.93% |
Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
Dec 31, 2021 | 208.38M | 195.77M | 1,551.57% |
Dec 31, 2020 | 12.62M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOVID News
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID - GlobeNewsWire
- 14 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID - GlobeNewsWire
- 20 days ago - Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations - GlobeNewsWire
- 21 days ago - Investors who lost money on Ovid Therapeutics Inc. should contact Levi & Korsinsky about an ongoing investigation - OVID - Accesswire
- 24 days ago - OVID ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Ovid Therapeutics Inc. Investment - Accesswire
- 25 days ago - Lost Money on Ovid Therapeutics Inc.(OVID)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Accesswire
- 4 weeks ago - What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? - Benzinga
- 5 weeks ago - Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat - GlobeNewsWire